Fulgent Genetics, Inc. (FLGT) Stock Grade

About Fulgent Genetics, Inc.'s fundamentals

Fulgent Genetics is a medical diagnostics company with a market capitalization of $635.0 million that generated revenue growth of 13.8% year-over-year, indicating expanding business activity in its core operations. However, the company is currently unprofitable, reporting a net margin of -18.8% and a net loss in its latest annual statement, meaning it is spending more than it generates in revenue. The company does not pay a dividend to shareholders. Given the lack of profitability metrics, traditional valuation measures like P/E ratio and return on equity are not applicable.